Overview

Selective Serotonin Reuptake Inhibitors, Fluoxetine Versus the Standard Oral Desmopressin for Management of Mono-symptomatic Nocturnal Enuresis.

Status:
Active, not recruiting

Trial end date:
2024-03-01

Target enrollment:

Participant gender:

Summary

To determine whether there is a role for the selective serotonin reuptake inhibitors fluoxetine versus desmopressin in the treatment of nocturnal enuresis in children who have not responded to standard nonpharmacological urotherapy, and whether there are side effects involved.

Phase:

N/A

Details

Lead Sponsor:

Fayoum University Hospital

Treatments:

Deamino Arginine Vasopressin
Fluoxetine